Biotest AG: Press Release- Biotest AG: 'Biotest sales and EBIT growth in first quarter; extension of credit facility'
Biotest AG / Quarter Results
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Press Release- Biotest AG: 'Biotest sales and EBIT growth in first quarter;
extension of credit facility'
- Q1 2009: Revenue Growth of 13% and EBIT increase of 8%
- Extension of Credit facility
Dreieich/ Frankfurt am Main, May 7, 2009 - In his speech at the Annual
General Meeting today, the Chairman of the Management Board, Prof. Dr.
Gregor Schulz announced sales and earnings before interest and tax (EBIT)
for the first quarter 2009. Sales in the first quarter 2009 increased by
13.2% to EUR 119.4 million. Earnings before Interest and Tax (EBIT)
accounted for EUR 14.4 million, which represents a growth of 8.3% compared
to the previous year's period.
The outlook for the year 2009 was confirmed with a planned increase in
sales of 10% and an EBIT on last year level of approx. EUR 55 million.
Furthermore, it was announced that as of May 6, 2009, Biotest concluded a
new credit facility. This credit facility complements the funding framework
of the syndicated loan agreement of November 2007 by an additional working
capital credit facility of EUR 40 million with a two years maturity.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a company that researches and manufactures pharmaceutical,
biotherapeutic and diagnostic products and has specialised in the areas of
application of immunology and haematology. In its Plasma Protein segment,
Biotest develops and markets immunoglobulins, coagulation factors and
albumins based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. In the Biotherapeutic segment, Biotest
researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and cancer of plasma
cells. The products of the Microbiological Monitoring segment are primarily
used in hygiene monitoring, while those of Medical Diagnostics are used,
for example, in blood transfusions and transplants. Biotest has around
2,000 employees worldwide. The shares of Biotest AG are listed in the SDAX
on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: monika_buttkereit@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
07.05.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
